diagnosis. The maximal LAA emptying velocity (LAAV) was recorded by placing the pulsed wave Doppler gate within 1 cm of the LAA orifice. Emp tying velocities of less than 20 cm/s were regarded as decreased. LA thrombus was defined as an in dependently mobile, round, oval, or irregularly shaped echodense structure, distinct from the sur rounding endocardium or pectinate muscles, and detected in more than 1 imaging plane. Dense SEC was defined as dynamic "smoke like" signal with a characteristic swirling motion, or a dynamic ge latinous precipitous echo density without a dis crete mass, present throughout the cardiac cycle. In our department, all TEE studies are recorded and stored; thus, they were available for reevalu ation during data collection for the current study. In patients with LAA thrombus, ablation or car dioversion was postponed and an intensified an ticoagulant regimen was initiated. study endpoints LAA thrombus on TEE was considered a study endpoint. Patients were not followed for periprocedural or postprocedural complications.
statistical analysis Continuous and ordinal vari ables were expressed as a median (interquartile range). Categorical data were presented as a num ber of patients and percentages. Group compari sons were performed using the t test for quantita tive variables, and the Fisher exact test for quali tative variables. To determine whether any clinical variables and anticoagulant regimens were relat ed to a relatively increased risk of LAA thrombus formation, univariate and multivariate logistic re gressions were performed. A multivariate logistic regression analysis was performed using clinical variables with a P value of 0.10 or less in a uni variate analysis. Coefficients from logistic regres sion were checked by the Wald test, and odds ra tios (ORs) and referring 95% confidence intervals (CIs) were derived. All tests were 2 tailed. All cal culations were performed using the SAS software, version 9.2 (SAS Institute, Cary, North Carolina, United States). For all analyses, a P value of less than 0.05 was considered statistically significant.
REsuLTs
Of 1033 patients with AF scheduled for AF ablation or cardioversion who underwent TEE, 174 patients were excluded from the current analysis: 116 patients underwent TEE without any prior OAC therapy, and in 58 patients bridging with unfractionated heparin or low molecular weight heparin was used. The clinical charac teristics as well as the frequency of LAA throm bus and dense SEC on TEE in patients with AF who did not receive any OAC, as compared with anticoagulant treated patients with AF who con stituted the study group are presented in Supple mentary material, Tables S1 and S2.
The study group consisted of 859 patients. A total of 437 patients (50.9%) were treated with VKAs; 191 (22.2%), with dabigatran; 230 (26.8%), with rivaroxaban; and 1 patient (0.1%), monitoring. 5-10 The most recent European Soci ety of Cardiology guidelines on AF favor NOAC over VKA treatment in nonvalvular AF. 1 How ever, in Poland, many patients with nonvalvu lar AF still receive VKAs instead of NOACs 11 be cause the latter are not reimbursed. Apart from the relatively high cost of NOAC therapy, some Polish physicians seem to believe that VKAs are superior to NOACs in terms of their anticoagu lant efficacy, despite evidence from randomized clinical trials. 9-10,12-16
The aim of the study was to compare the clini cal characteristics of Polish patients with AF treat ed with different anticoagulant regimens (VKAs and NOACs), as well as to assess the incidence of LAA thrombus and dense spontaneous echo contrast (SEC) in a real world population of pa tients with AF.
PATIENTs ANd mEThOds study population We performed a single center observational study of 1033 consecutive patients with AF, referred to our department between January 2012 and August 2016 for catheter ablation or direct cur rent cardioversion for AF. All demographic, clin ical, laboratory, and echocardiographic (includ ing TEE) data, as well as information on medica tion, were retrieved retrospectively from medi cal records. To compare anticoagulant efficacy of different oral anticoagulant (OAC) regimens, we excluded patients on no anticoagulant treatment, patients in whom OACs were discontinued dur ing the previous 3 weeks, and those who under went bridging with heparin before TEE.
Transesophageal echocardiography In our depart ment, TEE is performed routinely in all patients scheduled for pulmonary vein isolation or for di rect current cardioversion for AF (unless the lat ter is performed for emergency indications). TEE is routinely performed in all patients scheduled for cardioversion even if there are data indicat ing that it might be omitted. 17 All TEE studies are performed within 48 hours before the scheduled procedure (usually directly or within a few hours prior to the procedure). All TEE studies were performed in our echocardiog raphy laboratory (certified with grade C accredita tion of the Section of Echocardiography of the Pol ish Cardiac Society) using EPIQ 7 Ultrasound Ma chine (Philips Medical Systems, Andover, Massa chusetts, United States) or iE33 Ultrasound Ma chine (Philips Medical Systems), using a Philips X7 2t TEE ultrasound transducer (Philips Medical Systems). The LA cavity, including the LAA, was ex amined for the presence of a thrombus or SEC, in cluding dense SEC, by experienced echocardiogra phers (all certified with the second degree accred itation in echocardiography of the Echocardiog raphy Working Group of the Polish Cardiac Soci ety). Each TEE examination raising a suspicion of an LAA thrombus was assessed by 2 echocardiog raphers, and in case of doubt, by a third echocar diographer, to provide a reliable and unanimous cardioversions (n = 3) and ablations (n = 4) were subsequently performed.
In the rivaroxaban group, 92% of the patients were treated with a dose of 20 mg once daily and 8% received a dose of 15 mg once daily. In the VKA group, 296 patients (68%) were treated with acenocoumarol, and 141 (32%)-with war farin. There were no differences between the VKA and NOAC groups with respect to the baseline clinical characteristics (including the CHA 2 DS 2 VASc and HAS BLED scores), as well as to the fre quency of LAA thrombus (6.9% in the VKA group and 5.5% in the NOAC group; P = 0.40) and dense SEC (5.3% in the VKA group and 3.3% in with apixaban. In the dabigatran group, 89% of the patients received dabigatran at a dose of 150 mg twice daily; 6%, 110 mg twice daily; and 4%, 150 mg once daily. In the group of 7 patients who were given dabigatran at a dose of 150 mg once daily, 4 patients had persistent AF and 3 patients had paroxysmal AF. One patient was 78 years old, and 6 patients were treated with ami odarone in combination with dabigatran, which might have influenced the reduction of dabig atran dose in these patients. However, the rea son for prescribing the dose of 150 mg daily in stead of 110 mg twice daily is unknown. As no patient in this group (dabigatran, 150 mg once daily) presented with a thrombus on TEE, both There were no differences between the aceno coumarol and warfarin groups with respect to baseline clinical characteristics, but both groups differed in the frequency of LAA thrombus (8% in the acenocoumarol group and 4% in the war farin group; P = 0.07). The proportion of patients with LAA thrombus on TEE depending on OAC therapy is shown in FIGuRE 1.
In the logistic regression analysis, none of the OAC regimens predicted LAA thrombus on TEE. In univariate analyses, the predictors of LAA thrombus included age, type of AF (persistent and permanent vs paroxysmal), diabetes, heart the NOAC group; P = 0.18). Detailed character istics of the NOAC and VKA groups are present ed in TAbLEs 1 and 2.
Compared with patients treated with dabiga tran, those on rivaroxaban more often had par oxysmal AF. They also had higher ejection frac tion, LAAV, and platelet count, as well as lower left ventricular end diastolic dimension and hemato crit, with no other significant differences in clin ical characteristics (including the CHA 2 DS 2 VASc and HAS BLED scores). The frequency of LAA thrombus in both groups was comparable (6.8% in the dabigatran group vs 4.4% in the rivaroxa ban group; P = 0.29), while dense SEC more of ten occurred in dabigatran treated patients (5.2% (international normalized ratio, 2-3), and re cent studies have also suggested safety of un interrupted NOAC therapy in the periprocedur al period.
18-23 Moreover, a recent report revealed that in patients with AF undergoing catheter ab lation, uninterrupted anticoagulation with dab igatran reduces the number of major bleeding events compared with uninterrupted anticoag ulation with warfarin.
24
When the last dose of NOACs is taken at least 36 hours before the intervention, TEE should be considered before ablation.
2 In our department, routine TEE is performed before each cardiover sion and ablation, irrespective of the anticoagu lation strategy. This is because there is no coagu lation assay available for any NOAC that provides information on effective anticoagulation over the previous 3 weeks. Moreover, patient adher ence to NOAC treatment may be doubtful, and LA thrombus may occur even despite adequate VKA failure, a history of stroke, transient ischemic at tack or peripheral embolism, glomerular filtra tion rate, and maximal LAAV. All those variables were consequently included in the multivariate analysis. In the multivariate model, only maxi mal LAAV remained an independent predictor of LAA thrombus on TEE. The results of the uni variate and multivariate analyses of the predic tors of LAA thrombus are presented in Supple mentary material online, Table S3 . dIsCussION Based on the European Heart Rhythm Association and the European Society of Cardiology guidelines, in patients with AF last ing more than 48 hours (or AF of unknown du ration) undergoing cardioversion, effective OAC therapy should be given for at least 3 weeks pri or to cardioversion or TEE should be performed to exclude LA thrombi.
1,2 Left pulmonary vein isolation requires continuation of VKA therapy P values indicate differences between the dabigatran and rivaroxaban groups.
Abbreviations: see TAbLE 1 considered. 2 However, in our study, the choice of anticoagulation did not depend on patients' thromboembolic or bleeding risk, and there were no significant differences between patients treat ed with NOACs and those treated with VKAs with respect to clinical characteristics, including com ponents of the SAMe TT 2 R 2 score, which has been previously suggested as a helpful tool to predict the time in therapeutic range of less than 65% on VKA therapy, and thus to assist the decision making in choosing between a NOAC and VKA in treatment naive patients with AF. [26] [27] [28] [29] [30] Thus, the choice of a particular anticoagulant regimen or NOAC therapy. Approximately 50% of cen ters perform TEE in all patients undergoing left pulmonary vein isolation, regardless of the pre senting rhythm and of the CHADS 2 or CHA 2 DS 2 VASc score. 25 According to the updated European Heart Rhythm Association practical guidelines on the use of NOACs in patients with nonvalvular AF, the choice of anticoagulant (VKA or NOAC; type of NOAC) has to be made on the basis of a risk benefit analysis. Furthermore, patient related clinical factors and patient preference after discussion of different options need to be of dense SEC in the rivaroxaban group. However, this difference may be explained by higher emp tying LAA velocities, as well as lower hemato crit in the rivaroxaban group. Better LAA hemo dynamic function in the rivaroxaban group was probably related to a higher prevalence of parox ysmal (instead of persistent or permanent) AF. Still, despite these differences, the frequency of LAA thrombus formation in both NOAC groups was comparable.
Although it is beyond the scope of the present publication, it is worth noting that in the group receiving bridging therapy (58 patients), LAA thrombus was not observed. Previous nonran domized studies have shown that the strategy without the use of bridging anticoagulation is noninferior to that with the use of bridging ther apy for the prevention of arterial thromboembo lism. A meta analysis of observational studies in volving a total of 12 278 patients with AF or me chanical heart prostheses who received or did not receive bridging with low molecular weight hep arin showed no significant difference in the rate of arterial thromboembolism (OR with bridging, 0.80; 95% CI, 0.42-1.54), but a higher rate of ma jor bleeding (OR, 3.60; 95% CI, 1.52-8.50) in as sociation with bridging. 41 In our study, the lower prevalence of LAA thrombus in patients receiv ing bridging therapy may be related to a relative ly small number of patients in this group. Fur thermore, it needs to be emphasized that we did not assess the rate of bleeding complications in the study population.
Finally, it is worth noting that in our real life population of patients with AF referred for ab lation or cardioversion, 15% of the patients on OAC therapy had a CHA 2 DS 2 VASc score of 0 (with only 0.4% of patients having an indication for OAC therapy due to mechanical valve prosthe sis), and 24% of the patients receiving no form of OAC had a CHA 2 DS 2 VASc score of 2.
Our study adds to the knowledge on the effi cacy of NOAC in comparison with VKAs in real world population of patients with AF. Further more, it shows the prevailing trends in anticoag ulant treatment in Poland, as our center gained the status of a tertiary referral hospital and in the realworld population of patients with AF in our study seems to have been affected predom inantly by personal preferences of the attending physician or the patient (possibly including pa tients' financial capacities).
The results of our research indicate similar ef ficacy of different anticoagulant regimens in pre venting LAA thrombus formation. The frequen cies of LAA thrombus on VKA, dabigatran, and rivaroxaban therapies were 6.9%, 6.8%, and 4.4%, respectively. Recently, Kawabata et al 31 assessed the prevalence of LAA thrombi in 559 patients on at least a 3 week course of anticoagulation ther apy. Similarly to our study, they found no differ ence in the prevalence of LAA thrombi between patients on warfarin and those on NOACs (2.8% vs 2.6%; P = 0.86). 31 In most studies, the incidence of LA thrombus under VKA treatment ranged be tween 2% and 7.9%. 32-36 Thus, the present data are in line with these studies.
Compared with our study group, the frequen cy of LA thrombus in the RE LY trial 9 was signif icantly lower and reached 1.8%, 1.2%, and 1.1% in the group receiving dabigatran at a dose of 110 mg twice daily, the group receiving dabiga tran at a dose of 150 mg twice daily, and the VKA group, respectively. 9 The same applies to the com parison of our results to the study by Mitamura et al, 37 who reported the frequency of LA throm bus at 0.5% in patients treated with dabigatran at a dose of 150 mg twice daily and 3.5% in those treated with dabigatran at a dose of 110 mg twice daily. In the study by Reers et al, 38 LA thrombus was observed in 4% of patients treated with VKAs, 0% in patients treated with dabigatran, and 2% in patients treated with rivaroxaban. However, a study by Zylla et al 39 revealed a significantly higher prevalence of intracardiac thrombi in pa tients on VKA therapy (17.8%) than those on dab igatran (3.8%) or rivaroxaban (4.1%). In a study by Wyrembak et al, 40 the incidence of LAA throm bi was also higher in patients treated with war farin (1.55%), as compared with patients treated with NOACs (0.24%; P = 0.047).
Although we observed no difference in the prev alence of LAA thrombus between patients treat ed with dabigatran and those treated with rivar oxaban, there was a trend for a lower occurrence 
